drugset
drugset / Trial / NCT00277316

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

NCT00277316 ↗

Phase 2 Terminated 11 enrolled Symphony Evolution, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Timeline

Start
2005-12
Primary completion
2007-02
Completion
2007-06

Outcome

Outcome not reported

Stopped: “Development of XL999 was stopped due to cardiac toxicities in the subjects”

Drugs

EvaluationDrugModalityDoseRoute
Subject XL999 Small molecule 2.4 mg/kg Intravenous

Indications

renal cell carcinoma